Stock Events

Stock Events

Epigenomics 

€0.7000
12
-€0.09-11.17% Thursday 10:42

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

11AugExpected
Q3 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
-1.53
-0.96
-0.39
0.19
Expected EPS
0
Actual EPS
0.1853

Financials

-2,479.18%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
485,000Revenue
-12.02MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap21.67B
Guardant Health provides liquid biopsy tests for cancer detection, competing in the non-invasive cancer diagnostics market.
Illumina
ILMN
Mkt Cap32.55B
Illumina offers genomic sequencing technologies and services, enabling cancer detection and research that competes with Epigenomics' products.
Qiagen NV
QGEN
Mkt Cap8.9B
Qiagen provides sample and assay technologies for molecular diagnostics, including cancer, competing in the same space as Epigenomics.
Fulgent Genetics
FLGT
Mkt Cap539.57M
Fulgent Genetics offers genetic testing to detect cancer, among other conditions, competing with Epigenomics' diagnostic tests.
Myriad Genetics
MYGN
Mkt Cap302.25M
Pacific Biosciences of California
PACB
Mkt Cap435.16M
Pacific Biosciences offers sequencing systems that could be used in cancer research and diagnostics, indirectly competing with Epigenomics' diagnostic technologies.

About

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Show more...
CEO
Mr. Gregory K. Hamilton
Employees
36
Country
Germany
ISIN
DE000A37FT41
WKN
000A37FT4

Listings

MU
DE
ECX0.MU
STU
DE
ECX.STU
MU
DE
ECX.MU
LSE
GB
0QXH.LSE

0 Comments

Share your thoughts

FAQ

What is Epigenomics stock price today?▼
The current price of ECX.XETRA is €0.70 EUR — it has decreased by -11.17% in the past 24 hours. Watch Epigenomics stock price performance more closely on the chart.
What is Epigenomics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Epigenomics stocks are traded under the ticker ECX.XETRA.
What is Epigenomics revenue for the last year?▼
Epigenomics revenue for the last year amounts to 485,000 EUR.
What is Epigenomics net income for the last year?▼
ECX.XETRA net income for the last year is -12.02M EUR.
How many employees does Epigenomics have?▼
As of September 05, 2026, the company has 36 employees.
In which sector is Epigenomics located?▼
Epigenomics operates in the Health & Wellness sector.
When did Epigenomics complete a stock split?▼
Epigenomics has not had any recent stock splits.
Where is Epigenomics headquartered?▼
Epigenomics is headquartered in Berlin, Germany.